Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.82 |
| ▸ | PDE4A | P27815 | 15/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.70 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5336558 | 0.90 | KCNH2 (1.00) | KCNH2PDE4ACYP2C9PDE4BPDE4C | |
| SCHEMBL5352735 | 0.89 | KCNH2 (0.77) | KCNH2PDE4ACYP2C9PDE4BPDE4C | |
| SCHEMBL5336548 | 0.87 | KCNH2 (1.00) | KCNH2PDE4ACYP2C9PDE4BPDE4C | |
| SCHEMBL5943314 | 0.87 | KCNH2 (0.93) | KCNH2PDE4ACYP2C9PDE4BPDE4C | |
| SCHEMBL4714167 | 0.85 | PDE4A (0.75) | KCNH2PDE4ACYP2C9PDE4BPDE4C | |
| SCHEMBL5340138 | 0.85 | PDE4A (1.00) | KCNH2PDE4ACYP2C9PDE4BPDE4C | |
| SCHEMBL8247481 | 0.85 | PDE4A (0.83) | KCNH2PDE4ACYP2C9PDE4BPDE4C | |
| SCHEMBL5346164 | 0.85 | KCNH2 (0.89) | KCNH2PDE4ACYP2C9PDE4BPDE4C | |
| SCHEMBL5340791 | 0.85 | KCNH2 (0.74) | KCNH2PDE4ACYP2C9PDE4BPDE4C | |
| SCHEMBL5340317 | 0.84 | KCNH2 (1.00) | KCNH2PDE4ACYP2C9PDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312334-B2 | Method of preparing inhibitors phosphodiesterase-4 | MERCK & CO. INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312334-B2 | Method of preparing inhibitors phosphodiesterase-4 | MERCK & CO. INC. (US) | 2007-12-25 | — | — | US | disclosed |
| WO-2004048377-A2 | METHOD OF PREPARING INHIBITORS OF PHOSPHODIESTERASE-4 | MERCK & CO., INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20040102472-A1 | Method of preparing inhibitors of phosphodiesterase-4 | MERCK & CO., INC. | 2004-05-27 | — | — | US | disclosed |
| US-20040102472-A1 | Method of preparing inhibitors of phosphodiesterase-4 | MERCK & CO., INC. | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102472-A1 | Method of preparing inhibitors of phosphodiesterase-4 | PDE4B, PDE4A, PDE5A | KCNH2 722/4885PDE4A 2/4885CYP2C9 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.